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Background: Health care cost is rising. We aim to quantify the economic burden caused by inappropriate resource use in a chest pain cohort and 
seek the role of defensive medicine therein.
Methods: A 1-year cohort of 265 patients admitted with chest pain who underwent Myocardial Perfusion Imaging (MPI) was studied. Pretest 
probability was calculated using the Diamond and Forrester Score (DFS). Pretest probability at which a negative test would reduce the post-test 
probability to <10% was taken as <40% (based on sensitivity and specificity of 85% for MPI), and subjects were divided into two groups (Grp): 
DFS<40% (A) and DFS≥40% (B). Accuracy of MPI was studied in each group. Physicians ordering MPI for Grp A subjects were surveyed about role of 
defensive medicine. Cost of MPI, inpatient workup was analyzed.
Results: 











DFS<40% (Grp A) 219(82.6%) 13.67(7.32) 22(10%) 22(10%) 5(2.2%) 3(1.3%) 22.7%
DFS≥40% (Grp B) 46(17.4%) 68.48(13.2) 12(26%) 13(28%) 10(21.7%) 6(13%) 83.3%
P value NA 0.000 0.010 0.014 0.010 0.012 NA
Physician (MD) Survey: Response to role of defensive medicine (defined as the practice of ordering medical tests or procedures of limited clinical 
value with the partial goal of protecting the medical community from lawsuits) in ordering MPI for group A subjects (DFS<40%).
1. Significant (70-100%) role: 17%
2. Some (40-69%) role: 28%
3. No (0%) role: 55%
Only 10% of Grp A subjects had positive MPI, 2.2% had CAD; none were ruled in for Myocardial Infarction. Positive MPI was 3.6 times more likely 
to predict CAD in Grp B than Grp A. MD survey revealed that in 45% of Grp A subjects, there was a considerable role of defensive medicine in 
ordering the MPI. About $600 000/ year could have been saved at our hospital if MPI was not ordered in a group (Grp A) in which it has low positive 
predictive value; $4 500 000 if they had not been admitted. If the proportion of Grp A subjects is similar nationwide, billions could be saved.
Conclusion: Accurate risk stratification in chest pain patients can reduce cost without compromising safety. Defensive medicine increases 
resource utilization.
